| 查看: 650 | 回复: 4 | ||
| 【奖励】 本帖被评价3次,作者wangye增加金币 2 个 | ||
| 当前主题已经存档。 | ||
[资源]
Statistics In Drug Research
|
||
|
Statistics In Drug Research: Methodologies and Recent Developments (Biostatistics, 10) By Shein-Chung Chow Publisher: CRC Number Of Pages: 367 Publication Date: 2002 Sales Rank: 1460072 ISBN / ASIN: 082470763X EAN: 9780824707637 Binding: Hardcover Manufacturer: CRC Studio: CRC Average Rating: 5 Emphasizing the role of good statistical practices (GSP) in drug research and formulation, this book outlines important statistics applications for each stage of pharmaceutical development to ensure the valid design, analysis, and assessment of drug products under investigation and establish the safety and efficacy of pharmaceutical compounds. Coverage include statistical techniques for assay validation and evaluation of drug performance characteristics, testing population/individual bioequivalence and in vitro bioequivalence according to the most recent FDA guidelines, basic considerations for the design and analysis of therapeutic equivalence and noninferiority trials. Review: belongs on desk of every pharmaceutical biostatistician This is a very new and unique book that covers the gamut of statistical issues through all phases of drug development. Shao is a distinguished professor from Wisconsin and Chow teaches at Temple but is known for his long career in the pharmaceutical industry. The book is good for biostatisticians and regulatory affairs specialists as a reference source. All the key statistical issues are addressed and the reader is given the perspective of the ICH and FDA guidance documents. The underlying statistical methodology that justifies the recommendations in the guidances is presented. This is a state-of-the-art book. Shao and Pigeot produced some of the recent research in individual bioequivalence that established a bootstrap procedure as an appropriate way to construct confidence intervals for the problem. Their method is recommended in an FDA guidance document. But more than just this one example, all the key issues that have been the subject of FDA workshops over the past several years are addressed in this book. These topics include calibration, assay and assay validation, dissolution testing, stability analysis, shelf life estimation, bioequivalence, randomization and blinding, what constitutes substantive evidence in clinical development, therapeutic equivalence and noninferiority, Bayesian approaches in clinical trials, problems involving missing and incomplete data, longitudinal methods, meta-analysis, quality of life studies and instrument validation, and medical imaging. Other prevalent issues in clinical trials include group sequential methods, hierarchical Bayesian models and multiple testing. These issues are not covered as much in this text as the others we have mentioned. But there is some discussion of multiplicity in the context of quality of life studies. An example of sequential testing is used to illustrate model selection in Chapter 2. The important issues of design and sample size requirements are presented throughout the book. While not all topics are covered in sufficient depth, the book is remarkable in the breadth of material covered in just 350 pages of text. The authors also provide a very authoritative list of references and regulatory guidances and other documents.pass: gigapedia.org http://mihd.net/r6ko87 http://rapidshare.com/files/6271 ... arch_082470763X.rar |
» 猜你喜欢
面上项目filecode邪修
已经有6人回复
应该是93bebmhtak前后十一个字符比较关键
已经有14人回复
2026国自然放榜时间
已经有4人回复
关于代码变化问题,想知道的进来
已经有22人回复
这样的filecode谁见过
已经有21人回复
filecode与中标关系的预测
已经有5人回复
fileCode有新解读?
已经有18人回复
关于filecode,很负责任的告诉大家
已经有7人回复
【2027博士申请】纳米药物递送方向
已经有5人回复
关于豆爷回答的JTJC与%2F数量
已经有7人回复
2楼2007-10-18 14:47:28
3楼2007-10-18 19:23:13
4楼2007-10-19 15:03:58










回复此楼


无法下载?请指教!
20